Your trusted destination for CME, CPD & Medical Education across the Middle East.
BGICC 2027 covers breast cancer, gynecological oncology, immuno-oncology, precision medicine, cancer diagnostics, surgery, radiotherapy, and systemic treatment. Additional topics include molecular biomarkers, targeted and immune-based therapies, early detection, multidisciplinary cancer management, clinical research, and individualized treatment strategies.
The 19th Breast, Gynecological & Immuno-Oncology International Cancer Conference (BGICC 2027) brings together medical oncologists, surgical oncologists, radiation oncologists, gynecologic oncologists, pathologists, radiologists, researchers, and other cancer-care professionals. The conference focuses on advances in the prevention, diagnosis, treatment, and multidisciplinary management of breast and gynecological cancers. Key areas include breast cancer biology, early detection, molecular classification, neoadjuvant and adjuvant treatment, surgical management, and modern radiation therapy. The scientific program also addresses gynecological malignancies and evolving approaches to cervical, ovarian, endometrial, and other reproductive-system cancers. Immuno-oncology is an important component, with discussions around immunotherapy, targeted treatments, biomarkers, and strategies for developing more personalized cancer care. Advances in precision oncology, molecular diagnostics, imaging, clinical trials, and response-guided treatment may also be explored. Through expert lectures, multidisciplinary discussions, clinical cases, and international scientific exchange, BGICC 2027 provides a platform for sharing emerging evidence and improving cancer management and patient outcomes. The conference also supports collaboration among regional and international oncology communities in addressing evolving challenges in women's cancer care.
Updates on surgical and adjuvant therapies for early-stage disease.
Exploring novel systemic treatments and palliative care strategies.
Advancements in oncoplastic and minimally invasive breast surgeries.
Current trends in the medical and surgical management of ovarian cancer.
New screening guidelines and therapeutic approaches for cervical malignancies.
Recent clinical trials and targeted treatments for endometrial cancer.
The role of predictive and prognostic biomarkers in personalized medicine.
Clinical applications and resistance mechanisms of PARP inhibitors.
Evaluating the efficacy of immune checkpoint inhibitors in women's cancers.
Secure your seat and earn full credit eligibility with encrypted checkout.
Secure payment processing & PCI-aligned flow
| Registration | Category | Valid Until | Price |
|---|---|---|---|
| Egyptian delegates | Early Registration | — | USD 550 |
| Egyptian delegates | Late Registration | — | USD 650 |
| Non-Egyptian delegates | Early Registration | — | USD 800 |
| Non-Egyptian delegates | Late Registration | — | USD 900 |